Login / Signup

Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis.

Farida AhangariChristine BeckerDaniel G FosterMaurizio ChioccioliMeghan NelsonKeriann BekeXing WangAurelien JustetTaylor AdamsBenjamin ReadheadCarly MeadorKelly CorrellLoukia N LiliHelen M RoybalKadi-Ann RoseShuizi DingThomas BarnthalerNatalie BrionesGiuseppe DeIuliisJonas Christian SchuppQin LiNorihito OmoteYael AschnerLokesh SharmaKatrina W KopfBjörn MagnussonRyan HicksAnna BackmarkCharles S Dela CruzIvan RosasLeslie P CousensJoel T DudleyNaftali KaminskiGregory P Downey
Published in: American journal of respiratory and critical care medicine (2022)
These studies identify novel Src-dependent fibrogenic pathways and support the study of the therapeutic effectiveness of saracatinib in IPF treatment.
Keyphrases
  • pulmonary fibrosis
  • idiopathic pulmonary fibrosis
  • tyrosine kinase
  • randomized controlled trial
  • systematic review
  • systemic sclerosis
  • stem cells
  • cell therapy